Skip to main content

MED

National Cancer Institute to Host Media Briefing on TMIST Breast Cancer Research Trial

Oct 06, 2021 10:26AM ● By Med Magazine

Sanford Health and the National Cancer Institute (NCI) invite members of the media to attend a media briefing on the national Tomosynthesis Mammographic Imaging Screening Trial (TMIST), a breast cancer screening trial that will help personalize breast cancer screening for women to ensure all women are receiving the best possible care.

Sanford Health is the only health care system in North Dakota and the surrounding area enrolling patients in the trial. Sanford’s Roger Maris Cancer Center in Fargo has been enrolling patients since January. Sanford Bismarck started recruiting patients for the trial in July.

The media briefing will be held this Thursday, Oct. 7 from 11:30 a.m. to 1 p.m. CST.

Media only: Registration is required to attend via WebEx and ask questions. Participation will be approved in advance. Register here.

Speakers:

  • Worta McCaskill-Stevens, M.D., M.S., chief, Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, NCI, NIH
  • Etta Pisano, M.D., FACR, Ph.D., chief science officer, Center for Research and Innovation, American College of Radiology
  • Women participating in the trial will also share their experiences.

Dr. Preston Steen is the principal investigator for the study at Sanford. He will be available for interviews after the media briefing. Contact Sanford media relations at 701-200-6080.

TMIST, sponsored by NCI, is the first randomized trial to compare 2-D and 3-D digital mammography for breast cancer screening. Sanford Health has been enrolling healthy women ages 45 to 74 who are already planning to get routine mammograms to see which technology performs best.

Women who choose to participate are randomly assigned by a computer to receive a 2D or 3D mammogram for their routine screenings over five years (every two years for postmenopausal with no high-risk factors). After that time, participants can choose their screening options and will continue to be followed through their medical records for up to three more years.

Sanford collects participants’ mammography data and results, as well as important demographic information. To help researchers better understand the biology of breast cancer, participants may voluntarily contribute blood samples and genetic material to build a biorepository.

To be eligible for the trial, patients must not have had a screening mammogram within 11 months of enrolling and must:

  • be 45-75 years old at the time of enrollment
  • not be pregnant or breastfeeding
  • be scheduled for, or have an intent to schedule, a screening mammogram
  • have no new symptoms or signs of benign or malignant breast disease
  • not have a previous personal history of breast cancer
  • not have breast enhancements

Patients in the Fargo region interested in participating in the study should talk with their health care provider or call 701-234-7422.